Home
overview
Effective use of biomarkers at each stage of R&D can improve decision-making, increase clinical trial success rates and productivity and allow earlier stop/go decisions to be made, eliminating waste of resources, which can otherwise be re-deployed.

Companies taking advantage of and making best use of biomarkers in R&D are reaping the rewards of gaining the competitive edge.

Designed to focus specifically on oncology, The SMi Group's  Cancer Biomarkers Conference is an excellent opportunity for you to learn from industry leaders about how they are applying biomarkers to expedite cancer detection, drug discovery and development.

Our excellent panel of speakers includes:

  • Andreas Strauss, Head PDx Portfolio Management, Biomarker Program Oncology, Roche Diagnostics GmbH.
  • Dr Stephen Barnhill, Chairman & Chief Executive Officer, Health Discovery Corporation
  • Dr Herbert Fritsche, Professor, Laboratory Medicine and Chief, Clinical Chemistry Section, MD Anderson Cancer Center & Chairman, Scientific Advisory Board, Health Discovery Corporation
  • Dr Mark Rolfe, Vice President, Discovery Oncology, Millennium Pharmaceuticals
  • Dr Hans Winkler, Senior Director, Functional Genomics, Johnson & Johnson
  • Dr Peter Shaw, Senior Director, Clinical Oncology, Merck Research Laboratories
  • Professor Andrew Hughes, Worldwide Clinical Director, Discovery Medicine, AstraZeneca Oncology
  • Dr Philip Murphy, Director, Clinical Research & Development, Pfizer
  • Dr Sridhar K Rabindran, Associate Director, Oncology Research, Wyeth
  • Dr Paul McSheehy, Senior Research Investigator & Lab Head, Oncology Research, Novartis Pharma
  • Dr Hans-Juergen Arens, Manager, Medical & Scientific Development, Europe, Middle East & Africa, Abbott


The programme will be led by a panel of international experts, including:

By attending, you will benefit from hearing about:
  • UNRAVELLING the complexities of cancer
  • PREDICTIVE response markers in oncology
  • USING biomarkers as a novel tool in the diagnosis and treatment of cancer
  • WHERE the bottle necks lie in technology applications
  • TISSUE ANALYSIS and the development of pharmacodynamic end points for new cancer drugs
  • OVERCOMING obstacles in developing clinically useful biomarker tests
  • HOW cancer biomarkers can aid the decision-making process
  • VALIDATING your cancer biomarker
  • AND much more!

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Mark Rolfe

Mark Rolfe, Vice President, Discovery Oncology, Millennium Pharmaceuticals

9:10 USE OF SURROGATE BIOMARKERS AS A COMPANION DIAGNOSTIC

Herbert Fritsche

Herbert Fritsche, Professor, Laboratory Medicine and Chief, Clinical Chemistry Section, MD Anderson Cancer Center & Chairman, Scientific Advisory Board, Health Discovery Corporation

  • Companion diagnostic approach for BPH therapy
  • Large cost and time savings with accurate biomarkers
  • Favorable regulatory environment means faster to market



  • 9:50 UNRAVELING THE COMPLEXITIES OF CANCER

    Colin Hill

    Colin Hill, CEO, Gene Network Sciences

  • Is finding good quality biomarkers easier said than done?
  • Data-driven model extraction and simulation to identify drug MoA and biomarkers
  • Case study: selecting the optimal multi-kinase inhibitor for cancer treatment
  • Gene expression data versus proteomics. What is more valuable?
  • The next step in personalised medicine?
  • 10:30 Morning Coffee

    10:50 ASSAY VALIDATION FOR SUCCESSFUL BIOMARKER MEASUREMENT

    John Allinson

    John Allinson, Director, Veeda CR Ltd

  • Overview of Biomarker Assay “Issues”
  • Choice of Laboratory & scientific consensus
  • AAPS  - LBABFG Biomarker Committee
  • Validation recommendations
  • Case Studies
  • 11:30 BIOMARKER STRATEGIES AND ASSAY DEVELOPMENTS FOR CANCER THERAPEUTICS

    Andreas Strauss

    Andreas Strauss, Head PDx Portfolio Management, Biomarker Program Oncology, Roche Diagnostics GmbH

  • Lessons learnt from Herceptin
  • Matching clinical development with Biomarker needs
  • Where are the bottle necks in the technologies
  • Protein-based versus molecular technologies
  • 12:10 MICRORNA BIOMARKERS IN CANCER

    Søren M. Echwald

    Søren M. Echwald, Vice President, Business Development, Exiqon

  • MicroRNAs: A novel group of key regulatory molecules
  • MicroRNAs and Cancer
  • Locked Nucleic Acids: Perfectly matched for microRNA detection
  • 12:50 Networking Lunch

    13:50 CONTEXTUAL THERAPEUTICS FOR CANCER

    Mark Rolfe

    Mark Rolfe, Vice President, Discovery Oncology, Millennium Pharmaceuticals

  • Molecular discovery and early preclinical results
  • Methodologies, technologies and biochemical pathways
  • Considerations when choosing preclinical models
  • Phase I study design and patient recruitment
  • Preparing for phase I – a phase 0 study
  • 14:30 OBSTACLES IN DEVELOPING CLINICALLY USEFUL BIOMARKER TESTS

    Andrew Hughes

    Andrew Hughes, Director, Discovery Medicine, Cancer & Infection, AstraZeneca

  • Which biomarker (or biomarkers) should be used?
  • Designing a detection test with clinical value
  • What tissue/fluid should be tested? – considering ease of collection,
  • value, storage and efficacy
  • Method of detection, ease of use and storage
  • Clinical value versus cost
  • 15:10 Afternoon Tea

    15:30 RESPONSE PREDICTION AND COMPOUND DIFFERENTIATION IN KINASE DRUG DISCOVERY

    Matthias Versele

    Matthias Versele, Scientist, Oncology Discovery & Early Development, Johnson & Johnson

  • Response prediction to the multi-targeted tyrosine kinase inhibitor, MTKI (an EGFR/ Her family, VEGFR3/Flt4 and Src family kinase inhibitor) using peptide arrays
  • 16:10 TISSUE ANALYSIS AND THE DEVELOPMENT OF PHARMACODYNAMIC END POINTS FOR NEW CANCER DRUGS

    Karol Sikora

    Karol Sikora, Scientific Director, Medical Solutions and Professor of Cancer Medicine, Medical Solutions Plc

  • Determination of the maximal effective dose is essential for targeted compounds
  • New approaches using serial tumour biopsies are possible in phase I studies
  • Novel quantitative multiplex digitised assays based on histochemistry are now available
  • Determination of pharmacodynamic endpoint will speed up development times
  • Similar strategies will be used to discover predictive biomarkers of response
  • 16:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Bas van der Baan

    Bas van der Baan, Director, Business Development, Agendia BV

    9:10 MOLECULAR TESTS IN DISEASE MANAGEMENT - BEING MEANINGFUL IS WHAT COUNTS

    Hans-Juergen Arens

    Hans-Juergen Arens, Manager Medical & Scientific Development, Europe, Middle East & Africa, Abbott Gmb H

  • Testing for HER-2/neu
  • Diagnostic implications for HIV patient management
  • The promises of biomarkers
  • Predictive medicine – why does It make sense in oncology?
  • The theranostics approach
  • 9:50 THE USE OF CANCER BIOMARKERS IN THE DECISION MAKING PROCESSES IN CLINICAL TRIALS

    Peter Shaw

    Peter Shaw, Director, Oncology, Merck & Co.

  • Understanding variability
    - Human variation
    - Tumour variation
  • Diagnostic development
  • Recruiting the ‘right’ patients
  • 10:30 Morning Coffee

    10:50 A NEW BIOMARKER SIGNATURE FOR PROSTATE CANCER

    Stephen Barnhill

    Stephen Barnhill, Chairman & Chief Executive Officer, Health Discovery Corporation

  • Identifies clinically significant prostate cancer, AUC > 94%
  • SVM/RFE pattern recognition tools were essential to discovery
  • The beginning of the end for PSA?
  • The future of cancer testing: multiple biomarker expression signatures
  • 11:30 BIOMARKERS IN EARLY CLINICAL DEVELOPMENT OF NOVEL ANTICANCER THERAPEUTICS

    Michael Lahn

    Michael Lahn, Medical Advisor, Eli Lilly

  • Development of novel biomarker assays prior to starting Early Phase Clinical Trials
  • Application of biomarkers during the Phase II clinical development
  • 12:10 PET IMAGING IN CLINICAL TRIALS

    Eric Perlman

    Eric Perlman, Director, Molecular Imaging and Biomarkers, Radpharm

  • Practical aspects of PET in Oncology Imaging
  • Emerging Criteria for determination of response
  • Challenges of obtaining reliable quantitative data
  • Using PET/CT in Clinical Trials
  • Design and Limitations of PET in Multi-center Trials
  • 12:50 Networking Lunch

    13:50 IMAGING ENDPOINTS IN CLINICAL DEVELOPMENT

    Philip Murphy

    Philip Murphy, Director, Clinical Research and Development, Pfizer

  • An overview of currently accepted and standardised imaging methodologies
  • A review of technical developments that can challenge standardised implementation
  • A review of emerging technologies that can potentially inform drug development
  • How do we develop and validate new techniques?
  • 15:10 Afternoon Tea

    15:30 BIOMARKERS IN THE CLINICAL DEVELOPMENT OF HKI-272

    Sridhar Rabindran

    Sridhar Rabindran, Associate Director, Oncology, Wyeth

  • A brief description of the in vitro and in vivo preclinical activity of HKI-272
  • Summary of preliminary phase I data
  • Identification of predictive and efficacy biomarkers for clinical development
  • Challenges faced in applying biomarker strategy, and opportunities for improvement
  • 16:10 VALIDATING YOUR CANCER BIOMARKER

    Janusz Jankowski

    Janusz Jankowski, , University Of Oxford

  • Overcoming challenges in the efficacy testing of your cancer agent
  • Ensuring specificity
  • Dosages and side effects
  • 16:50 Chairman’s Closing Remarks and Close of Conference

    +

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.